tradingkey.logo

Journey Medical Corp

DERM
8.350USD
0.0000.00%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
220.21MCap. mercado
PérdidaP/E TTM

Journey Medical Corp

8.350
0.0000.00%

Más Datos de Journey Medical Corp Compañía

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Información de Journey Medical Corp

Símbolo de cotizaciónDERM
Nombre de la empresaJourney Medical Corp
Fecha de salida a bolsaNov 12, 2021
Director ejecutivoMaraoui (Claude)
Número de empleados41
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 12
Dirección9237 E Via De Ventura Blvd., Suite 105
CiudadSCOTTSDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal85258
Teléfono14804346670
Sitio Webhttps://journeymedicalcorp.com/
Símbolo de cotizaciónDERM
Fecha de salida a bolsaNov 12, 2021
Director ejecutivoMaraoui (Claude)

Ejecutivos de Journey Medical Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+20000.00%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
17.63M
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%

Estadísticas de accionistas

Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
Otro
64.95%
Accionistas
Accionistas
Proporción
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
Otro
64.95%
Tipos de accionistas
Accionistas
Proporción
Corporation
12.33%
Individual Investor
12.01%
Hedge Fund
11.42%
Investment Advisor
10.13%
Investment Advisor/Hedge Fund
9.10%
Private Equity
0.84%
Insurance Company
0.66%
Research Firm
0.31%
Pension Fund
0.15%
Otro
43.05%

Participación institucional

Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
2023Q3
44
2.15M
17.23%
+484.38K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fortress Biotech Inc
3.36M
15.9%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.75%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
8.77%
--
--
Sep 30, 2025
Wasatch Global Investors Inc
1.31M
6.18%
+154.21K
+13.39%
Sep 30, 2025
Opaleye Management Inc.
971.06K
4.59%
+876.06K
+922.17%
Sep 30, 2025
The Vanguard Group, Inc.
615.23K
2.91%
+50.24K
+8.89%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
571.92K
2.71%
+91.62K
+19.08%
Sep 30, 2025
Summit Financial, LLC
379.83K
1.8%
+379.83K
--
Sep 30, 2025
Rosenwald (Lindsay A)
377.89K
1.79%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
354.02K
1.68%
+125.82K
+55.13%
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Royce Quant Small-Cap Quality Value ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI